The changing picture of community acquired urinary tract infections in the US: a daunting prospect

INTRODUCTION: Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, yet rising antimicrobial resistance is rapidly eroding the effectiveness of standard oral therapies. Resistance to fluoroquinolones and trimethoprim-sulfamethoxazole exceeding 40% among uropathogenic Escherichia coli - driven largely by multidrug-resistant and extended‑spectrum β‑lactamase (ESBL) - producing Enterobacterales strains such as ST131-are fueling increased reliance on parenteral agents, emergency department visits, and hospitalizations. AREAS COVERED: This commentary reviews the current US epidemiology of UTI, including the growing burden of ESBL-producing Enterobacterales and the pandemic ST131 lineage, and summarizes contemporary resistance and co-resistance patterns among key uropathogens. It highlights oral agents approved or under review in the US, including pivmecillinam, sulopenem, and gepotidacin, each approved for uncomplicated UTI, as well as tebipenem pivoxil hydrobromide, which if approved, would represent the first oral carbapenem option for selected complicated UTIs, and discusses antimicrobial stewardship principles for community UTI management. Established first-line agents are referenced in the context of resistance trends but are not reviewed comprehensively, as this commentary focuses specifically on recently approved and investigational oral agents. EXPERT OPINION: Recently approved or emerging oral agents offer a meaningful opportunity to reduce dependence on intravenous carbapenems and avoid some hospitalizations, but uptake may be constrained by cost pressures, limited post-marketing experience, and stewardship concerns. Pharmacoeconomic analyses incorporating avoided admissions and patient convenience will be essential. Judiciously deployed within stewardship frameworks, these agents have potential to reduce the clinical and economic burden of multidrug-resistant UTI, contingent on further real-world evidence and pharmacoeconomic data.